levofloxacin has been researched along with naproxen in 15 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 4,551 | 1,057 | 1,429 |
| Protein | Taxonomy | levofloxacin (IC50) | naproxen (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 1.1642 | |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | 1.2 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.0203 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.8725 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.06 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.5867 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 1.26 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 3.36 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 5.8 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andrade, RJ; Carrascosa, MF; Caviedes, JR; Lavín, AC; Lucena, MI; Mones, JC; Rivero, AP; Serrano, VB | 1 |
| Kruhlak, NL; Zhu, X | 1 |
| Huo, Y; Jiang, Y; Wu, Y | 1 |
| Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
1 review(s) available for levofloxacin and naproxen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for levofloxacin and naproxen
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection.
Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Doxycycline; Fatal Outcome; Hepatitis; Humans; Levofloxacin; Liver Failure, Acute; Male; Middle Aged; Naproxen; Ofloxacin; Pericarditis; Pneumonia, Mycoplasma | 2009 |
Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data.
Topics: Algorithms; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Bile Duct Diseases; Calibration; Chemical and Drug Induced Liver Injury; Cholestasis; Data Mining; Databases, Factual; Drug Labeling; Endpoint Determination; Humans; Levofloxacin; Liver; Naproxen; Product Surveillance, Postmarketing; Quantitative Structure-Activity Relationship; Toxicity Tests; Vitamins | 2014 |
Thermo-responsive hydrogels with N-isopropylacrylamide/acrylamide interpenetrating networks for controlled drug release.
Topics: Absorbable Implants; Acrylamide; Acrylamides; Delayed-Action Preparations; Drug Liberation; Hydrogels; Levofloxacin; Materials Testing; Molecular Structure; Naproxen; Polyethylene Glycols; Porosity; Temperature; Water | 2015 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |